{"title":"Comprehensive Analysis of Immunobiological Effects and Prognostic Significance Related to Endoplasmic Reticulum Stress in Pancreatic Carcinoma.","authors":"Zhuyi Zhou, Min Shi, Guoxiong Zhou","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Pancreatic cancer (PC) has a poor response to the many treatments available for it, including surgery, chemotherapeutics, targeted therapy, and immunotherapy. It's crucial to investigate alternative methods of prognostic assessment and decision-making in choosing a therapy, making it necessary to explore its differentially expressed genes (DEGs).</p><p><strong>Objective: </strong>The study intended to assess the role of endoplasmic reticulum stress (ERS)-related genes (ERSRGs) in PC to create an effective, prognostic risk-prediction model and potential immunotherapy options.</p><p><strong>Design: </strong>The research team performed a genetic study.</p><p><strong>Setting: </strong>The study took place at the Affiliated Hospital of Nantong University in Nantong, Jiangsu, China.</p><p><strong>Outcome measures: </strong>The research team: (1) performed molecular subtype identification and analysis, (2) developed a prognostic risk model, (3) evaluated the clinical features of the risk model, (4) identified the clinicopathological features affecting survival, (5) analyzed the potential immune roles in ERS, (6) constructed five gene signatures associated with ERS, (7) examined the association between different risk categories and sensitivity to GDSC drugs as a potential predictor of response to chemotherapy , and (8) identified the biological processes associated with different risk categories.</p><p><strong>Results: </strong>Significant differences existed in the survival prognosis of subtype C and subtype A or B (P < .001). The high-risk group with the lower TIDE score had a significantly better response to immunotherapy (P < .0057). The high-risk group had a significantly higher somatic mutation rate (P < .00017) and a worse survival prognosis (P < .001). Differences in mRNA expression existed for ERAP2 (P < .001), IGF2BP2 (P = .006), DSG3 (P = .001), MAPK10 (P = .006), and PRKCSH (P ≤ .015) in clinical samples.</p><p><strong>Conclusions: </strong>Through the analysis of ERS subtypes of pancreatic cancer, the study found that the infiltration abundance of stromal cells and immune cells can affected by ERS, thus changing the prognosis of patients. The predictive model provides reference values for clinical prognosis and immunotherapy for PC patients through its ability to evaluate patients' immune statuses. Clinical treatment can provide individualized guidance and can effectively predict the prognosis of PC patients.</p>","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Pancreatic cancer (PC) has a poor response to the many treatments available for it, including surgery, chemotherapeutics, targeted therapy, and immunotherapy. It's crucial to investigate alternative methods of prognostic assessment and decision-making in choosing a therapy, making it necessary to explore its differentially expressed genes (DEGs).
Objective: The study intended to assess the role of endoplasmic reticulum stress (ERS)-related genes (ERSRGs) in PC to create an effective, prognostic risk-prediction model and potential immunotherapy options.
Design: The research team performed a genetic study.
Setting: The study took place at the Affiliated Hospital of Nantong University in Nantong, Jiangsu, China.
Outcome measures: The research team: (1) performed molecular subtype identification and analysis, (2) developed a prognostic risk model, (3) evaluated the clinical features of the risk model, (4) identified the clinicopathological features affecting survival, (5) analyzed the potential immune roles in ERS, (6) constructed five gene signatures associated with ERS, (7) examined the association between different risk categories and sensitivity to GDSC drugs as a potential predictor of response to chemotherapy , and (8) identified the biological processes associated with different risk categories.
Results: Significant differences existed in the survival prognosis of subtype C and subtype A or B (P < .001). The high-risk group with the lower TIDE score had a significantly better response to immunotherapy (P < .0057). The high-risk group had a significantly higher somatic mutation rate (P < .00017) and a worse survival prognosis (P < .001). Differences in mRNA expression existed for ERAP2 (P < .001), IGF2BP2 (P = .006), DSG3 (P = .001), MAPK10 (P = .006), and PRKCSH (P ≤ .015) in clinical samples.
Conclusions: Through the analysis of ERS subtypes of pancreatic cancer, the study found that the infiltration abundance of stromal cells and immune cells can affected by ERS, thus changing the prognosis of patients. The predictive model provides reference values for clinical prognosis and immunotherapy for PC patients through its ability to evaluate patients' immune statuses. Clinical treatment can provide individualized guidance and can effectively predict the prognosis of PC patients.
期刊介绍：
Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field.
Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
